Loading clinical trials...
Loading clinical trials...
An Observational Retrospective Cohort Study of Lenalidomide Monotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) to Generate a Historical Control for Clinical Trial MOR208C203 (RE-MIND)
This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial MOR208C203 (L-MIND)
Tafasitamab (MOR00208) is currently in development for the treatment of R/R DLBCL. An ongoing, single-arm, phase II, open label, multicenter study (MOR208C203) is evaluating the efficacy and safety of tafasitamab combined with lenalidomide in patients with R/R DLBCL. In order to establish a lenalidomide monotherapy as a control cohort, this observational study aims to collect retrospective lenalidomide monotherapy data from real-world-evidence and to compare it with the tafasitamab-lenalidomide combination therapy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
MorphoSys Research Site
Rochester, Minnesota, United States
MorphoSys Research Site
St Louis, Missouri, United States
MorphoSys Research Site
Manhasset, New York, United States
MorphoSys Research Site
New York, New York, United States
MorphoSys Research Site
Rochester, New York, United States
MorphoSys Research Site
Dublin, Ohio, United States
MorphoSys Research Site
Charleston, South Carolina, United States
MorphoSys Research Site
Greenville, South Carolina, United States
MorphoSys Research Site
Bordeaux, France
MorphoSys Research Site
Le Mans, France
Start Date
April 12, 2019
Primary Completion Date
August 25, 2019
Completion Date
August 25, 2020
Last Updated
August 24, 2022
490
ACTUAL participants
Lead Sponsor
MorphoSys AG
NCT05006716
NCT06026319
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions